BRPI1006519A2 - formulação de anticorpos - Google Patents
formulação de anticorposInfo
- Publication number
- BRPI1006519A2 BRPI1006519A2 BRPI1006519A BRPI1006519A BRPI1006519A2 BR PI1006519 A2 BRPI1006519 A2 BR PI1006519A2 BR PI1006519 A BRPI1006519 A BR PI1006519A BR PI1006519 A BRPI1006519 A BR PI1006519A BR PI1006519 A2 BRPI1006519 A2 BR PI1006519A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody formulation
- antibody
- formulation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15833109P | 2009-03-06 | 2009-03-06 | |
| PCT/US2010/026410 WO2010102241A1 (en) | 2009-03-06 | 2010-03-05 | Antibody formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1006519A2 true BRPI1006519A2 (pt) | 2016-08-09 |
Family
ID=42154725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1006519A BRPI1006519A2 (pt) | 2009-03-06 | 2010-03-05 | formulação de anticorpos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8318161B2 (pt) |
| EP (1) | EP2403874A1 (pt) |
| JP (1) | JP2012519706A (pt) |
| KR (1) | KR20110128333A (pt) |
| CN (1) | CN102414221A (pt) |
| AR (1) | AR076640A1 (pt) |
| AU (1) | AU2010221156A1 (pt) |
| BR (1) | BRPI1006519A2 (pt) |
| CA (1) | CA2754528A1 (pt) |
| CL (1) | CL2011002194A1 (pt) |
| IL (1) | IL214956A0 (pt) |
| MX (1) | MX2011009306A (pt) |
| PE (1) | PE20120359A1 (pt) |
| RU (1) | RU2011140498A (pt) |
| SG (1) | SG174258A1 (pt) |
| TW (1) | TW201039854A (pt) |
| WO (1) | WO2010102241A1 (pt) |
| ZA (1) | ZA201106503B (pt) |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1043320A1 (zh) | 1999-06-01 | 2002-09-13 | Biogen, Inc. | Vla-1的一种阻塞性单系抗体，以及其治疗炎性失调的功用 |
| US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| PL367324A1 (en) | 2001-04-13 | 2005-02-21 | Biogen, Inc. | Antibodies to vla-1 |
| EP3178492A1 (en) | 2003-04-04 | 2017-06-14 | Genentech, Inc. | High concentration antibody and protein formulations |
| EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | SELF-BUFFING PROTEIN FORMULATIONS |
| EP2034830B1 (en) | 2006-05-25 | 2014-09-03 | Biogen Idec MA Inc. | Anti-vla-1 antibody for treating stroke |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| US20110275791A1 (en) * | 2009-01-06 | 2011-11-10 | Ziad Mallat | A B Cell Depleting Agent for the Treatment of Atherosclerosis |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| ES2765657T3 (es) * | 2009-12-21 | 2020-06-10 | Hoffmann La Roche | Formulación farmacéutica de bevacizumab |
| AU2013202276B2 (en) * | 2009-12-21 | 2016-03-24 | Genentech, Inc. | Antibody formulation |
| SI2542257T1 (en) | 2010-03-01 | 2018-01-31 | Bayer Healthcare Llc | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) |
| CN103124564B (zh) | 2010-03-22 | 2016-11-09 | 弗·哈夫曼-拉罗切有限公司 | 对于稳定含有蛋白质的制剂有用的组合物和方法 |
| JP5953303B2 (ja) | 2010-07-29 | 2016-07-20 | ゼンコア インコーポレイテッド | 改変された等電点を有する抗体 |
| FI2616090T3 (fi) | 2010-09-17 | 2023-09-21 | Baxalta GmbH | Immunoglobuliinien stabilointi vesipitoisen histidiiniä sisältävän valmisteen avulla pH:ssa, joka on lievästi happamasta neutraaliin |
| MY158130A (en) * | 2010-10-06 | 2016-08-30 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor )il-4r) antibodies |
| UA111731C2 (uk) * | 2010-10-06 | 2016-06-10 | Рідженерон Фармасьютікалз, Інк. | Стабілізована композиція, яка містить антитіло до рецептора інтерлейкіну-4 (іl-4r), варіанти |
| PH12013501576A1 (en) | 2011-01-28 | 2013-09-30 | Sanofi Biotechnology | Pharmaceutical compositions comprising human antibodies to pcsk9 |
| WO2012149228A1 (en) * | 2011-04-26 | 2012-11-01 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| CA2848201C (en) | 2011-09-16 | 2020-10-27 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9) |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| KR102259829B1 (ko) * | 2011-10-31 | 2021-06-03 | 제넨테크, 인크. | 항체 제제 |
| EP2807190B1 (en) | 2012-01-23 | 2018-12-26 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ang2 antibodies |
| MX370199B (es) * | 2012-02-16 | 2019-12-05 | Santarus Inc | Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a). |
| AR092325A1 (es) | 2012-05-31 | 2015-04-15 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
| FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| KR101419884B1 (ko) | 2012-11-27 | 2014-07-16 | (주)알테오젠 | 단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물 |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| CN110981964B (zh) | 2013-01-14 | 2023-09-15 | Xencor股份有限公司 | 新型异二聚体蛋白 |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| AU2014207549B2 (en) * | 2013-01-15 | 2018-12-06 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| EP3421495A3 (en) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| JP6462681B2 (ja) | 2013-07-12 | 2019-01-30 | ジェネンテック， インコーポレイテッド | イオン交換クロマトグラフィーのインプットの最適化の解明 |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| CN113350278B (zh) * | 2013-10-24 | 2023-03-24 | 阿斯利康(瑞典)有限公司 | 稳定的水性抗体配制品 |
| MX2016006226A (es) | 2013-11-12 | 2016-09-07 | Sanofi Biotechnology | Regimenes de dosificacion para uso con inhibidores de pcsk9. |
| AU2015217572B2 (en) | 2014-02-11 | 2020-10-15 | Visterra, Inc. | Antibody moleules to dengue virus and uses thereof |
| RS59907B1 (sr) | 2014-03-28 | 2020-03-31 | Xencor Inc | Bispecifična antitela koja se vezuju za cd38 i cd3 |
| WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| CA2955294A1 (en) | 2014-07-16 | 2016-01-21 | Sanofi Biotechnology | Methods for treating patients with heterozygous familial hypercholesterolemia (hefh) |
| SG10201902915VA (en) | 2014-10-01 | 2019-04-29 | Eagle Biologics Inc | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| US9821059B2 (en) | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| AU2015346444A1 (en) | 2014-11-12 | 2017-05-04 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| SG11201704283PA (en) | 2014-11-26 | 2017-06-29 | Xencor Inc | Heterodimeric antibodies that bind cd3 and tumor antigens |
| US10526417B2 (en) | 2014-11-26 | 2020-01-07 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CD38 |
| US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| CA2995645A1 (en) | 2015-08-18 | 2017-02-23 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
| US11623957B2 (en) | 2015-12-07 | 2023-04-11 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
| JP7155009B2 (ja) | 2016-03-25 | 2022-10-18 | ビステラ， インコーポレイテッド | デングウイルスに対する抗体分子の製剤 |
| US10434141B2 (en) | 2016-05-31 | 2019-10-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
| US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
| LT3468586T (lt) | 2016-06-14 | 2024-12-10 | Xencor, Inc. | Bispecifiniai antikūnai prieš imuninės sistemos kontrolės taškų inhibitorius |
| MX2018016265A (es) | 2016-06-28 | 2019-07-04 | Xencor Inc | Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina. |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| NZ793452A (en) | 2016-10-14 | 2025-09-26 | Xencor Inc | IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS |
| SG11201903521XA (en) | 2016-10-21 | 2019-05-30 | Amgen Inc | Pharmaceutical formulations and methods of making the same |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| MA49517A (fr) | 2017-06-30 | 2020-05-06 | Xencor Inc | Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène |
| AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| CN111655718B (zh) | 2017-12-19 | 2025-07-22 | Xencor股份有限公司 | 经过工程化的il-2 fc融合蛋白 |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| JP2021519790A (ja) * | 2018-04-02 | 2021-08-12 | アムジェン インコーポレイテッド | エレヌマブ組成物及びその使用 |
| EP3773911A2 (en) | 2018-04-04 | 2021-02-17 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| US12024561B2 (en) | 2018-04-10 | 2024-07-02 | Dr. Reddy's Laboratories Limited | Stable antibody formulation |
| JP2021521784A (ja) | 2018-04-18 | 2021-08-30 | ゼンコア インコーポレイテッド | ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用 |
| EP3781598A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| US11690912B2 (en) * | 2018-05-29 | 2023-07-04 | Abcentra, Llc | Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody |
| EP3817768A4 (en) * | 2018-07-02 | 2022-07-06 | Abcentra, LLC | Compositions and methods for reduction of lipoprotein a formation and treatment of aortic valve sclerosis and aortic stenosis |
| WO2020072821A2 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| CN114173875B (zh) | 2019-03-01 | 2025-04-15 | Xencor股份有限公司 | 结合enpp3和cd3的异二聚抗体 |
| CA3145621A1 (en) * | 2019-08-16 | 2021-02-25 | Mary Kleppe | High concentration anti-c5 formulations |
| US20220403013A1 (en) * | 2019-11-12 | 2022-12-22 | Abcentra, Llc | Methods and compositions for treating cancer |
| CN115297838A (zh) * | 2020-02-24 | 2022-11-04 | 麦迪穆医学免疫有限责任公司 | 抗内皮脂肪酶抗体的制剂 |
| CA3182368A1 (en) | 2020-05-01 | 2021-11-04 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| CA3182940A1 (en) * | 2020-05-28 | 2021-12-02 | Kashiv Biosciences, Llc | An improved process of storing and preparing the protein formulation |
| TW202222832A (zh) | 2020-07-31 | 2022-06-16 | 美商建南德克公司 | 抗整聯蛋白β７抗體調配物及裝置 |
| CN117157319A (zh) | 2021-03-09 | 2023-12-01 | Xencor股份有限公司 | 结合cd3和cldn6的异二聚抗体 |
| JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体 |
| KR102839278B1 (ko) * | 2022-03-02 | 2025-07-30 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체의 월 1회 투여 방법 |
| KR102839225B1 (ko) * | 2022-03-02 | 2025-07-29 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체의 주 1회 투여 방법 |
| KR102868672B1 (ko) * | 2022-03-02 | 2025-10-14 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체를 2주마다 1회 투여하는 방법 |
| AU2023367497A1 (en) * | 2022-10-26 | 2025-05-15 | Nihon Medi-Physics Co., Ltd. | Radioactive pharmaceutical composition |
| EP4680632A2 (en) | 2023-03-17 | 2026-01-21 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| TW202500585A (zh) * | 2023-06-23 | 2025-01-01 | 瑞士商諾佛 儂迪克保健股份公司 | 每兩個月投予一次fviii模擬雙特異性抗體之方法 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1064396A (en) * | 1975-02-18 | 1979-10-16 | Myer L. Coval | Fractional precipitation of gamma globulin with polyethylene glycol |
| US4075193A (en) * | 1976-11-26 | 1978-02-21 | Parke, Davis & Company | Process for producing intravenous immune globulin |
| AT359641B (de) | 1978-09-19 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates |
| US4374763A (en) | 1979-09-17 | 1983-02-22 | Morishita Pharmaceutical Co., Ltd. | Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof |
| US4499073A (en) * | 1981-08-24 | 1985-02-12 | Cutter Laboratories, Inc. | Intravenously injectable immune serum globulin |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4597966A (en) | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
| US4940782A (en) * | 1987-06-08 | 1990-07-10 | G. D. Searle & Co. | Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore |
| ES2044941T5 (es) | 1987-08-21 | 1999-02-16 | Mallinckrodt Group Inc | Estabilizador de hormonas promotoras del crecimiento. |
| US4877608A (en) * | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| CA1331133C (en) * | 1988-03-01 | 1994-08-02 | Michael Jon Pikal | Pharmaceutical growth hormone formulations |
| US5262296A (en) * | 1988-03-30 | 1993-11-16 | Toray Industries, Inc. | Freeze-dried composition containing enzyme-labeled anti-human interferon-β antibody and enzyme immunoassay kit containing the composition |
| US5215743A (en) * | 1988-04-13 | 1993-06-01 | Maninder Singh | Tumor necrosis factor formulations |
| US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
| GB2218703B (en) * | 1988-05-10 | 1992-10-28 | Sumitomo Chemical Co | Human monoclonal antibody to p.aeruginosa: its production and use |
| EP0417193B1 (en) | 1988-05-27 | 1993-08-04 | Centocor, Inc. | Freeze-dried formulation for antibody products |
| JPH04504253A (ja) | 1989-03-27 | 1992-07-30 | セントカー・インコーポレーテツド | ＩｇＭ抗体の安定化のための配合物 |
| ZA902663B (en) | 1989-04-07 | 1991-12-24 | Syntex Inc | Interleukin-1 formulation |
| DE4001451A1 (de) | 1990-01-19 | 1991-08-01 | Octapharma Ag | Stabile injizierbare loesungen von faktor viii und faktor ix |
| JPH0565233A (ja) | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
| WO1992017207A1 (en) | 1991-03-26 | 1992-10-15 | Tanox Biosystems, Inc. | MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS |
| JP2966592B2 (ja) | 1991-07-20 | 1999-10-25 | 萩原 義秀 | 安定化されたヒトモノクローナル抗体製剤 |
| US6329509B1 (en) * | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
| EP0602126B1 (en) | 1991-08-14 | 2003-03-05 | Genentech, Inc. | Immunoglobulin variants for specific fc epsilon receptors |
| US6699472B2 (en) * | 1991-08-14 | 2004-03-02 | Genentech, Inc. | Method of treating allergic disorders |
| GB9120304D0 (en) | 1991-09-24 | 1991-11-06 | Erba Carlo Spa | Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor |
| US5849700A (en) * | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
| CH684164A5 (de) | 1992-01-10 | 1994-07-29 | Rotkreuzstiftung Zentrallab | Intravenös anwendbare Immunglobulinlösung. |
| EP0638091B1 (en) * | 1992-04-30 | 2005-12-07 | Probitas Pharma Inc. | Improved solubilization and stabilization of factor viii complex |
| DE4344824C1 (de) | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
| CA2184581C (en) | 1994-03-04 | 2005-02-22 | Hak-Kim Chan | Improved dnase liquid solutions |
| US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| GB9418092D0 (en) * | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
| AU4451396A (en) | 1994-12-28 | 1996-07-19 | Rhone-Poulenc Chimie | Optically active diphosphines and method for preparing same by resolution of the racemic mixture |
| US6037453A (en) * | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| ES2434840T3 (es) | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
| US6686191B1 (en) | 1995-09-22 | 2004-02-03 | Bayer Healthcare Llc | Preparation of virally inactivated intravenously injectable immune serum globulin |
| US5770700A (en) | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
| CA2244209C (en) * | 1996-01-25 | 2007-10-23 | Schering Aktiengesellschaft | Improved concentrated injection and infusion solutions for intravenous administration |
| KR100236393B1 (ko) | 1996-02-02 | 1999-12-15 | 나까니시 히로유끼 | 사람성장호르몬을 함유하는 의약제제 |
| CA2539273C (en) | 1996-02-09 | 2014-02-04 | Amgen Inc. | A fusion protein comprising an interleukin-1 receptor antagonist and uses thereof |
| TWI240627B (en) | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
| GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
| US6096872A (en) * | 1997-10-14 | 2000-08-01 | Ortho Diagnostic Systems, Inc. | Viral clearance process |
| US6541606B2 (en) * | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
| WO2000015260A1 (en) | 1998-09-16 | 2000-03-23 | Tanox, Inc. | Anti-ige gene therapy |
| GB9820525D0 (en) * | 1998-09-21 | 1998-11-11 | Allergy Therapeutics Ltd | Formulation |
| JP2000247903A (ja) | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
| NZ535205A (en) * | 1999-10-04 | 2006-01-27 | Chiron Corp | Stabilized liquid interleukin-2 ( IL-2 ) containing pharmaceutical compositions |
| US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| GB0023383D0 (en) * | 2000-09-23 | 2000-11-08 | Synprotec Ltd | 3,5-Bis (Trifluormethyl)Benzene derivatives |
| CN1469756A (zh) | 2000-10-11 | 2004-01-21 | 江头健辅 | 治疗肝病的药物 |
| PT1324776E (pt) * | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
| KR20030074693A (ko) | 2000-12-28 | 2003-09-19 | 알투스 바이올로직스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| DE60235013D1 (de) * | 2001-07-25 | 2010-02-25 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| EP1441748A4 (en) * | 2001-10-16 | 2007-07-11 | Rxkinetix Inc | HIGHLY CONCENTRATED PROTEIN FORMULATIONS AND MANUFACTURING METHOD |
| ATE556591T1 (de) * | 2001-11-08 | 2012-05-15 | Abbott Biotherapeutics Corp | Stabile pharmazeutische flüssigformulierung von igg-antikörpern |
| CA2500895A1 (en) * | 2002-10-04 | 2004-04-15 | Forskarpatent I Syd Ab | Peptide-based passive immunization therapy for treatment of atherosclerosis |
| AU2003293543A1 (en) * | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| EP3178492A1 (en) * | 2003-04-04 | 2017-06-14 | Genentech, Inc. | High concentration antibody and protein formulations |
| US20050158303A1 (en) * | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| US20060051347A1 (en) * | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| KR20080098504A (ko) * | 2006-02-03 | 2008-11-10 | 메디뮨 엘엘씨 | 단백질 제제 |
| PE20081610A1 (es) * | 2007-01-09 | 2008-12-09 | Wyeth Corp | Formulaciones de anticuerpos anti-il-13 y usos de los mismos |
| RU2470628C2 (ru) * | 2007-12-28 | 2012-12-27 | Биоинвент Интернешнл Аб | Состав |
| CN102711823A (zh) * | 2009-08-28 | 2012-10-03 | 基因泰克公司 | 使用抗氧化的ldl抗体治疗的方法 |
-
2010
- 2010-03-05 CN CN2010800194416A patent/CN102414221A/zh active Pending
- 2010-03-05 KR KR1020117023363A patent/KR20110128333A/ko not_active Ceased
- 2010-03-05 CA CA2754528A patent/CA2754528A1/en not_active Abandoned
- 2010-03-05 WO PCT/US2010/026410 patent/WO2010102241A1/en not_active Ceased
- 2010-03-05 US US12/718,783 patent/US8318161B2/en not_active Expired - Fee Related
- 2010-03-05 EP EP10707789A patent/EP2403874A1/en not_active Withdrawn
- 2010-03-05 AU AU2010221156A patent/AU2010221156A1/en not_active Abandoned
- 2010-03-05 JP JP2011553145A patent/JP2012519706A/ja not_active Withdrawn
- 2010-03-05 TW TW099106511A patent/TW201039854A/zh unknown
- 2010-03-05 SG SG2011063922A patent/SG174258A1/en unknown
- 2010-03-05 PE PE2011001591A patent/PE20120359A1/es not_active Application Discontinuation
- 2010-03-05 MX MX2011009306A patent/MX2011009306A/es not_active Application Discontinuation
- 2010-03-05 AR ARP100100676A patent/AR076640A1/es unknown
- 2010-03-05 RU RU2011140498/10A patent/RU2011140498A/ru not_active Application Discontinuation
- 2010-03-05 BR BRPI1006519A patent/BRPI1006519A2/pt not_active IP Right Cessation
-
2011
- 2011-09-04 IL IL214956A patent/IL214956A0/en unknown
- 2011-09-06 CL CL2011002194A patent/CL2011002194A1/es unknown
- 2011-09-06 ZA ZA2011/06503A patent/ZA201106503B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2403874A1 (en) | 2012-01-11 |
| RU2011140498A (ru) | 2013-04-20 |
| CA2754528A1 (en) | 2010-09-10 |
| MX2011009306A (es) | 2011-10-13 |
| AU2010221156A1 (en) | 2011-09-22 |
| JP2012519706A (ja) | 2012-08-30 |
| WO2010102241A1 (en) | 2010-09-10 |
| PE20120359A1 (es) | 2012-04-13 |
| CL2011002194A1 (es) | 2012-07-20 |
| US20100239567A1 (en) | 2010-09-23 |
| US8318161B2 (en) | 2012-11-27 |
| IL214956A0 (en) | 2011-11-30 |
| CN102414221A (zh) | 2012-04-11 |
| AR076640A1 (es) | 2011-06-29 |
| KR20110128333A (ko) | 2011-11-29 |
| ZA201106503B (en) | 2012-11-28 |
| TW201039854A (en) | 2010-11-16 |
| SG174258A1 (en) | 2011-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20250029I1 (fi) | neratinibi | |
| BRPI1006519A2 (pt) | formulação de anticorpos | |
| BRPI0922730A2 (pt) | formulação de anticorpo | |
| EP2358392A4 (en) | ANTIBODY FORMULATION | |
| FIC20230025I1 (fi) | neratinibi | |
| DK2459167T3 (da) | SUBKUTAN ANTI-HER2-antistofformulering | |
| PT2406284T (pt) | Anticorpos anti-bcma | |
| BRPI0820819A2 (pt) | Formulação de anticorpos | |
| BR112012030311A2 (pt) | anticorpo | |
| HUE038962T2 (hu) | DLL3-ellenes antitest | |
| BRPI0907237A2 (pt) | Anticorpo anti-cldn6 | |
| HRP20171011T1 (hr) | ANTI-eMET ANTITIJELO | |
| ZA201204266B (en) | Antibody formulation | |
| ZA201203242B (en) | Antibody formulation | |
| DK2462134T3 (da) | N1-sulfonyl-5-fluorpyrimidinonderivater | |
| PL3089450T3 (pl) | Łączenie obszarów próbek | |
| ES2897500T8 (es) | Formulaciones de anticuerpos T1h | |
| EP2482848A4 (en) | Endoglin antibodies | |
| DK3620175T3 (da) | Højkoncentrerede antistofformuleringer | |
| BRPI1009465A2 (pt) | Formulação | |
| EP2629796A4 (en) | ANTIBODY | |
| BRPI1008070A2 (pt) | tricianoboratos | |
| BR112012004964A2 (pt) | girocóptero | |
| EP2426149A4 (en) | ANTI-CADHERIN ANTIBODY | |
| EP2479211A4 (en) | FLUOR RUBBER COMPOSITION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |